Literature DB >> 20171992

The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways.

Diego Guidolin1, Giovanna Albertin, Barbara Oselladore, Elisa Sorato, Piera Rebuffat, Alessandra Mascarin, Domenico Ribatti.   

Abstract

Human vascular endothelial cells express the urotensin-II (U-II) receptor and exhibit a strong in vitro angiogenic response to the peptide. Thus, in the present study an in vitro model, based on human umbilical vein endothelial cells (HUVEC) cultured on Matrigel, was used to characterize more in detail the signaling pathways that control the pro-angiogenic action of U-II. The activation of the U-II receptor (UT) was associated with an increase of intracellular calcium concentration. Both calcium rise and pro-angiogenic effect of the peptide can be blocked by U73122, a selective inhibitor of phospholipase-C, indicating that the signal transduction from UT mainly involves the phospholipase-C/IP(3) pathway. As far as the downstream signaling pathways are concerned, western blot analyses and experiments with specific inhibitors indicated that the U-II-induced self-organization of the cells into capillary-like structures was PKC dependent and involved the activation of the ERK1/2, but not p38-MAPK, transduction pathway. Interestingly, the pharmacological inhibition of PI3K (obtained with LY294002), hindered the capacity of U-II to induce a proangiogenic effect on HUVEC, suggesting that PI3K-dependent pathways also play a role in regulating the process. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171992     DOI: 10.1016/j.regpep.2010.02.009

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  7 in total

1.  Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by p38 MAPK and ERK activations.

Authors:  Xiao Dong; Xiaojin Ye; Nana Song; Jing Zhao; Beibing Di; Fen Peng; Chaoshu Tang; Wenhui Ding
Journal:  Heart Vessels       Date:  2012-09-30       Impact factor: 2.037

2.  Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.

Authors:  N D Doan; T T M Nguyen; M Létourneau; K Turcotte; A Fournier; D Chatenet
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Authors:  A M D Watson; M Olukman; C Koulis; Y Tu; D Samijono; D Yuen; C Lee; D J Behm; M E Cooper; K A M Jandeleit-Dahm; A C Calkin; T J Allen
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

4.  Up-regulation of urotensin II and its receptor contributes to human hepatocellular carcinoma growth via activation of the PKC, ERK1/2, and p38 MAPK signaling pathways.

Authors:  Xiao-Tong Yu; Peng-Yan Wang; Zheng-Ming Shi; Kun Dong; Ping Feng; Hong-Xia Wang; Xue-Jiang Wang
Journal:  Molecules       Date:  2014-12-12       Impact factor: 4.411

5.  Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity.

Authors:  Laurence Desrues; Thomas Lefebvre; Céline Lecointre; Marie-Thérèse Schouft; Jérôme Leprince; Vincent Compère; Fabrice Morin; François Proust; Pierrick Gandolfo; Marie-Christine Tonon; Hélène Castel
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

6.  Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells.

Authors:  Chung-Yi Lee; Yi-Tin Tsai; Shih-Hurng Loh; Ju-Chi Liu; Tso-Hsiao Chen; Hung-Hsing Chao; Tzu-Hurng Cheng; Jin-Jer Chen
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

7.  Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours.

Authors:  Benjamin Poret; Laurence Desrues; Marc-André Bonin; Martin Pédard; Martine Dubois; Richard Leduc; Romain Modzelewski; Pierre Decazes; Fabrice Morin; Pierre Vera; Hélène Castel; Pierre Bohn; Pierrick Gandolfo
Journal:  Biomolecules       Date:  2020-03-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.